tetano
Editor, Senior Moderator
PLoS One. 2010 Apr 14;5(4):e10176.
Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.
Alvarez MM, L?pez-Pacheco F, Aguilar-Ya?ez JM, Portillo-Lara R, Mendoza-Ochoa GI, Garc?a-Echauri S, Freiden P, Schultz-Cherry S, Zertuche-Guerra MI, Bulnes-Abundis D, Salgado-Gallegos J, Elizondo-Montemayor L, Hern?ndez-Torre M.
Centro de Biotecnolog?a-FEMSA, Tecnol?gico de Monterrey, Monterrey, New Le?n, M?xico. mario.alvarez@itesm.mx
Abstract
BACKGROUND: Although it has been estimated that pandemic Influenza A H1N1/2009 has infected millions of people from April to October 2009, a more precise figure requires a worldwide large-scale diagnosis of the presence of Influenza A/H1N1/2009 antibodies within the population. Assays typically used to estimate antibody titers (hemagglutination inhibition and microneutralization) would require the use of the virus, which would seriously limit broad implementation. METHODOLOGY/PRINCIPAL FINDINGS: An ELISA method to evaluate the presence and relative concentration of specific Influenza A/H1N1/2009 antibodies in human serum samples is presented. The method is based on the use of a histidine-tagged recombinant fragment of the globular region of the hemagglutinin (HA) of the Influenza A H1N1/2009 virus expressed in E. coli. CONCLUSIONS/SIGNIFICANCE: The ELISA method consistently discerns between Inf A H1N1 infected and non-infected subjects, particularly after the third week of infection/exposure. Since it does not require the use of viral particles, it can be easily and quickly implemented in any basic laboratory. In addition, in a scenario of insufficient vaccine availability, the use of this ELISA could be useful to determine if a person has some level of specific antibodies against the virus and presumably at least partial protection.
PMID: 20418957 [PubMed - in process]
Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.
Alvarez MM, L?pez-Pacheco F, Aguilar-Ya?ez JM, Portillo-Lara R, Mendoza-Ochoa GI, Garc?a-Echauri S, Freiden P, Schultz-Cherry S, Zertuche-Guerra MI, Bulnes-Abundis D, Salgado-Gallegos J, Elizondo-Montemayor L, Hern?ndez-Torre M.
Centro de Biotecnolog?a-FEMSA, Tecnol?gico de Monterrey, Monterrey, New Le?n, M?xico. mario.alvarez@itesm.mx
Abstract
BACKGROUND: Although it has been estimated that pandemic Influenza A H1N1/2009 has infected millions of people from April to October 2009, a more precise figure requires a worldwide large-scale diagnosis of the presence of Influenza A/H1N1/2009 antibodies within the population. Assays typically used to estimate antibody titers (hemagglutination inhibition and microneutralization) would require the use of the virus, which would seriously limit broad implementation. METHODOLOGY/PRINCIPAL FINDINGS: An ELISA method to evaluate the presence and relative concentration of specific Influenza A/H1N1/2009 antibodies in human serum samples is presented. The method is based on the use of a histidine-tagged recombinant fragment of the globular region of the hemagglutinin (HA) of the Influenza A H1N1/2009 virus expressed in E. coli. CONCLUSIONS/SIGNIFICANCE: The ELISA method consistently discerns between Inf A H1N1 infected and non-infected subjects, particularly after the third week of infection/exposure. Since it does not require the use of viral particles, it can be easily and quickly implemented in any basic laboratory. In addition, in a scenario of insufficient vaccine availability, the use of this ELISA could be useful to determine if a person has some level of specific antibodies against the virus and presumably at least partial protection.
PMID: 20418957 [PubMed - in process]